Johnson & Johnson (FRA:JNJ)
148.52
+1.20 (0.81%)
At close: Aug 8, 2025, 10:00 PM CET
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.74B USD in the quarter ending June 29, 2025, with 5.77% growth. This brings the company's revenue in the last twelve months to $90.63B, up 4.68% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$90.63B
Revenue Growth
+4.68%
P/S Ratio
4.63
Revenue / Employee
$656.24K
Employees
138,100
Market Cap
357.83B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Rheinmetall AG | 10.48B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Johnson & Johnson News
- 2 days ago - August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys - Seeking Alpha
- 4 days ago - Why Johnson & Johnson Stock Still Has Room To Run - Seeking Alpha
- 7 days ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025) - Seeking Alpha
- 7 days ago - The 3 Things That Matter for Johnson & Johnson Now - The Motley Fool
- 8 days ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 8 days ago - Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
- 8 days ago - Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
- 8 days ago - Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says - Forbes